Skip to main content
NewslettersWatchlist

Iqvia Holdings Inc(IQV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low230.06
Day High234.74
Open:230.92
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Barchart
Stocks Rebound as Bond Yields Fall on Dovish Fed Comments
Barchart
Stocks Rebound as Comments from Fed’s Goolsbee Knock Bond Yields Lower
Barchart
Markets Today: Stocks Rebound from Tuesday’s Slump as Bond Yields Decline
Barchart
Stocks Climb on Hopes for Favorable CPI Report on Wednesday
Motley Fool
2 Soaring Healthcare Stocks That Could Climb Even Higher
Motley Fool
Is Veeva Systems a Buy Now?
Business Wire
Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute
Business Wire
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance
Business Wire
IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023
Business Wire
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
Motley Fool
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
Business Wire
Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute
Business Wire
IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023
Business Wire
IQVIA Publishes its 2022 Environmental, Social and Governance Report
Motley Fool
Got $300? 3 Growth Stocks to Buy That Could Double Your Money
Business Wire
IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance
Business Wire
IQVIA Named to FORTUNE’s 2023 List of “World’s Most Admired Companies,” Ranked #1 in Its Category for the Second Consecutive Year
Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Business Wire
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
Business Wire
IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023
Business Wire
Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute
Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
PR Newswire
Lasso announces a significant step forward in healthcare marketing measurement
PR Newswire
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Business Wire
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
Business Wire
IQVIA Reports Third-Quarter 2022 Results
Motley Fool
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Business Wire
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
Business Wire
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
Business Wire
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
Business Wire
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

Profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speed innovation and accelerate improvements. I

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.